Time Warner Cable Inc. (NYSE:TWC): Netflix (NASDAQ:NFLX) is much more concerned about TV Everywhere (CMCSA, TWC) and similar services than over-the-top pure players like Amazon Prime (NASDAQ:AMZN) and Hulu Plus, according to a letter to shareholders sent following its Q4 earnings, reported The Next Web. Shares of Time Warner Cable Inc. are trading 7.08% higher today.
Caterpillar Inc. (NYSE:CAT): The company said, “Prospects for economic growth have improved over the past quarter, and we expect the world economy to grow about 3.3% in 2012, a small improvement from about 2.8% in 2011. In response to economic concerns, some central banks began easing policies late in 2011. Underpinning our growth expectations for 2012, we expect this easing to continue and contribute to the improvement in growth…Our outlook assumes most commodity prices will increase slightly in 2012 and continue at levels that encourage investment. We expect that copper will average over $4 per pound, Central Appalachian coal about $75 per ton and West Texas Intermediate crude oil about $100 per barrel.” Shares of Caterpillar Inc. are trading 3.33% higher today.
RealNetworks Inc (NASDAQ:RNWK): RealNetworks (NASDAQ:RNWK) announced that it has signed an agreement to sell a significant number of its patents and its next generation video codec software to Intel (NASDAQ:INTC) for a purchase price of $120M. Under terms of the sale, RealNetworks retains certain rights to continue to use the patents in current and future products. In addition to the sale of the patents and next-generation video codec software, RealNetworks and Intel signed a memorandum of understanding to collaborate on future support and development of the next-generation video codec software and related products. Shares of RealNetworks Inc are trading 33.03% higher today.
Micromet Inc. (NASDAQ:MITI): Amgen (NASDAQ:AMGN) and Micromet (NASDAQ:MITI) announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16B, was unanimously approved by both the Amgen and Micromet Boards of Directors. The acquisition includes blinatumomab, a Bispecific T cell Engager, or BiTE, antibody in Phase 2 clinical development for acute lymphoblastic leukemia, or ALL. Blinatumomab is also in clinical development for the treatment of non-Hodgkin’s lymphoma, or NHL, and could have applications in other hematologic malignancies. The tender offer is not subject to a financing condition. The transaction is expected to close in Q1. Shares of Micromet Inc. are trading 31.88% higher today.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org